1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Arthritis - Pipeline Review, H2 2014

Arthritis - Pipeline Review, H2 2014

  • July 2014
  • -
  • Global Markets Direct
  • -
  • 154 pages

Arthritis - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Arthritis - Pipeline Review, H2 2014’, provides an overview of the Arthritis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Arthritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Arthritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Arthritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Arthritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Arthritis - Pipeline Review, H2 2014
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Arthritis Overview 8
Therapeutics Development 9
Pipeline Products for Arthritis - Overview 9
Pipeline Products for Arthritis - Comparative Analysis 10
Arthritis - Therapeutics under Development by Companies 11
Arthritis - Therapeutics under Investigation by Universities/Institutes 15
Arthritis - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Arthritis - Products under Development by Companies 20
Arthritis - Products under Investigation by Universities/Institutes 22
Arthritis - Companies Involved in Therapeutics Development 23
Eli Lilly and Company 23
GlaxoSmithKline plc 24
Nemucore Medical Innovations, Inc. 25
Taisho Pharmaceutical Co., Ltd. 26
Sylentis S.A. 27
Astellas Pharma Inc. 28
Eisai Co., Ltd. 29
Bone Medical Limited 30
Momenta Pharmaceuticals, Inc. 31
Can-Fite BioPharma Ltd. 32
Lexicon Pharmaceuticals, Inc. 33
CSL Limited 34
WhanIn Pharmaceutical Co., Ltd. 35
Oscotec Inc. 36
Viron Therapeutics, Inc. 37
PLx Pharma Inc. 38
Endocyte, Inc. 39
Cardax Pharmaceuticals, Inc. 40
Taiwan Liposome Company, Ltd. 41
NasVax Ltd. 42
CalciMedica, Inc. 43
Zyngenia, Inc. 44
SelectX Pharmaceuticals, Inc. 45
DoNatur GmbH 46
CellAct Pharma GmbH 47
Arcarios BV 48
Inbiopro Solutions Pvt. Ltd. 49
Sagene Pharmaceuticals, Inc. 50
vida therapeutics inc. 51
Dong-A Socio Group 52
Arthritis - Therapeutics Assessment 53
Assessment by Monotherapy Products 53
Assessment by Combination Products 54
Assessment by Target 55
Assessment by Mechanism of Action 59
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 67
vancomycin hydrochloride - Drug Profile 67
PL-1100 - Drug Profile 68
MCS-18 - Drug Profile 69
GLPG-0555 - Drug Profile 71
LY-3114062 - Drug Profile 72
CSL-324 - Drug Profile 73
VT-346 - Drug Profile 74
CF-602 - Drug Profile 75
CDX-085 - Drug Profile 76
PL-5100 - Drug Profile 78
EC-1496 - Drug Profile 79
AMAP-102 - Drug Profile 80
ABC-294640 - Drug Profile 82
Anti-CD3 Oral Immunotherapy - Drug Profile 84
IBPB-001PH - Drug Profile 86
selegiline + NSAIDs - Drug Profile 87
AS-1940477 - Drug Profile 88
dexamethasone acetate - Drug Profile 89
MDC-917 - Drug Profile 90
Small Molecules to Inhibit MMP - Drug Profile 91
CAP-2.1 - Drug Profile 92
CAP-2.2 - Drug Profile 93
CAP1.1 - Drug Profile 94
Recombinant Protein to Inhibit TNF-Alpha for Inflammatory Diseases - Drug Profile 95
Small Molecules to Inhibit C-Rel for Central Nervous System, Musculoskeletal, Respiratory and Metabolic Disorders - Drug Profile 96
OXT-328 - Drug Profile 97
Peptide to Inhibit Intracellular IL-1 Receptor for Musculoskeletal, Dermatology and Central Nervous System Disorders - Drug Profile 99
Peptides to Inhibit MHC Class I and II for CNS Disorders and Musculoskeletal - Drug Profile 100
Antibody for Autoimmune Disorders and Inflammation - Drug Profile 101
DCB-3503 - Drug Profile 102
AT-132 - Drug Profile 103
TASP-0415914 - Drug Profile 104
fluticasone propionate - Drug Profile 105
Monoclonal Antibody to Inhibit Ang-2 and TNF-a - Drug Profile 106
CIIF-4 - Drug Profile 107
OA-1 - Drug Profile 108
TLC-599 - Drug Profile 109
Monoclonal Antibody to Inhibit CCL20 for Arthritis and Contact Hypersensitivity - Drug Profile 110
Small Molecule to Activate S100A8 for Arthritis - Drug Profile 111
CM-3457 - Drug Profile 112
Drugs to Activate P58IPK for Arthritis - Drug Profile 113
IMSB-001 - Drug Profile 114
RNAi Oligonucleotide for Arthritis and Gastrointestinal Disorders - Drug Profile 115
BN-005 - Drug Profile 116
BN-008 - Drug Profile 117
Small Molecule to Inhibit SYK for Arthritis - Drug Profile 118
Small Molecule to Inhibit ADAMTS-5 for Arthritis - Drug Profile 119
WIP-901C - Drug Profile 120
Small Molecules to Inhibit Cyclophilins - Drug Profile 121
Drug for Chronic Inflammatory Diseases - Drug Profile 123
Peptides to Inhibit Fibrinogen and ICAM-1 for Oncology, Inflammtion, Arthritis, Cardiovascular Disease and Bleeding Disorders - Drug Profile 124
Peptides to Inhibit TNF-a for Immunology, Oncology and Musculoskeletal Disorders - Drug Profile 125
Small Molecules to Inhibit CD147 for Immunology, Oncology, Womens Health and Musculoskeletal Disorders - Drug Profile 126
Small Molecules to Modulate BMP-2 for Arthritis - Drug Profile 127
FIV-based siRNA - Drug Profile 128
Gene Therapy for Arthritis - Drug Profile 129
NMI-4100 - Drug Profile 130
Arthritis - Recent Pipeline Updates 131
Arthritis - Dormant Projects 135
Arthritis - Discontinued Products 137
Arthritis - Product Development Milestones 138
Featured News and Press Releases 138
Appendix 149
Methodology 149
Coverage 149
Secondary Research 149
Primary Research 149
Expert Panel Validation 149
Contact Us 150
Disclaimer 150

List of Tables

Number of Products under Development for Arthritis, H2 2014 13
Number of Products under Development for Arthritis - Comparative Analysis, H2 2014 14
Number of Products under Development by Companies, H2 2014 16
Number of Products under Development by Companies, H2 2014 (Contd..1) 17
Number of Products under Development by Companies, H2 2014 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2014 20
Comparative Analysis by Late Stage Development, H2 2014 21
Comparative Analysis by Clinical Stage Development, H2 2014 22
Comparative Analysis by Early Stage Development, H2 2014 23
Products under Development by Companies, H2 2014 24
Products under Development by Companies, H2 2014 (Contd..1) 25
Products under Investigation by Universities/Institutes, H2 2014 26
Arthritis - Pipeline by Eli Lilly and Company, H2 2014 27
Arthritis - Pipeline by GlaxoSmithKline plc, H2 2014 28
Arthritis - Pipeline by Nemucore Medical Innovations, Inc., H2 2014 29
Arthritis - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2014 30
Arthritis - Pipeline by Sylentis S.A., H2 2014 31
Arthritis - Pipeline by Astellas Pharma Inc., H2 2014 32
Arthritis - Pipeline by Eisai Co., Ltd., H2 2014 33
Arthritis - Pipeline by Bone Medical Limited, H2 2014 34
Arthritis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2014 35
Arthritis - Pipeline by Can-Fite BioPharma Ltd., H2 2014 36
Arthritis - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2014 37
Arthritis - Pipeline by CSL Limited, H2 2014 38
Arthritis - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2014 39
Arthritis - Pipeline by Oscotec Inc., H2 2014 40
Arthritis - Pipeline by Viron Therapeutics, Inc., H2 2014 41
Arthritis - Pipeline by PLx Pharma Inc., H2 2014 42
Arthritis - Pipeline by Endocyte, Inc., H2 2014 43
Arthritis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2014 44
Arthritis - Pipeline by Taiwan Liposome Company, Ltd., H2 2014 45
Arthritis - Pipeline by NasVax Ltd., H2 2014 46
Arthritis - Pipeline by CalciMedica, Inc., H2 2014 47
Arthritis - Pipeline by Zyngenia, Inc., H2 2014 48
Arthritis - Pipeline by SelectX Pharmaceuticals, Inc., H2 2014 49
Arthritis - Pipeline by DoNatur GmbH, H2 2014 50
Arthritis - Pipeline by CellAct Pharma GmbH, H2 2014 51
Arthritis - Pipeline by Arcarios BV, H2 2014 52
Arthritis - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 53
Arthritis - Pipeline by Sagene Pharmaceuticals, Inc., H2 2014 54
Arthritis - Pipeline by vida therapeutics inc., H2 2014 55
Arthritis - Pipeline by Dong-A Socio Group, H2 2014 56
Assessment by Monotherapy Products, H2 2014 57
Assessment by Combination Products, H2 2014 58
Number of Products by Stage and Target, H2 2014 61
Number of Products by Stage and Mechanism of Action, H2 2014 65
Number of Products by Stage and Route of Administration, H2 2014 68
Number of Products by Stage and Molecule Type, H2 2014 70
Arthritis Therapeutics - Recent Pipeline Updates, H2 2014 135
Arthritis - Dormant Projects, H2 2014 139
Arthritis - Discontinued Products, H2 2014 141

List of Figures

Number of Products under Development for Arthritis, H2 2014 13
Number of Products under Development for Arthritis - Comparative Analysis, H2 2014 14
Number of Products under Development by Companies, H2 2014 15
Number of Products under Investigation by Universities/Institutes, H2 2014 19
Comparative Analysis by Clinical Stage Development, H2 2014 22
Comparative Analysis by Early Stage Products, H2 2014 23
Assessment by Monotherapy Products, H2 2014 57
Number of Products by Top 10 Target, H2 2014 59
Number of Products by Stage and Top 10 Target, H2 2014 60
Number of Products by Top 10 Mechanism of Action, H2 2014 63
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 64
Number of Products by Top 10 Route of Administration, H2 2014 67
Number of Products by Stage and Top 10 Route of Administration, H2 2014 68
Number of Products by Top 10 Molecule Type, H2 2014 69
Number of Products by Stage and Top 10 Molecule Type, H2 2014 70

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global phototherapy equipment market is projected to reach USD 583.4 million by 2021, growing at a CAGR of 4.5% during the forecast period of 2016 to 2021. This market is primarily driven by the huge ...

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global antinuclear antibody (ANA) testing market is expected to reach USD 1,476.1 million by 2021 from USD 823.5 million in 2016, at a CAGR of 12.4%. The global ANA testing market is segmented based ...

Interstitial Cystitis  - Market Insights, Epidemiology and Market Forecast-2023

Interstitial Cystitis  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Interstitial Cystitis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.